Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
European Urology Oncology|January 6, 2024
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder CancerRoger Li, Luigi Nocera, Kyle M Rose, et al.
Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.
European Urology Oncology|May 3, 2022
Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial CarcinomaAlberto Martini, Chiara Lonati, Luigi Nocera, et al.
Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
BJU International|October 7, 2023
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancerAndrea Necchi, Giuseppe Basile, Ewan A Gibb, et al.
Nature Communications|April 27, 2023
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancerA Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, et al.
European Urology Oncology|May 18, 2020
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 StudyAndrea Necchi, Daniele Raggi, Patrizia Giannatempo, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
Nature Reviews. Urology|August 16, 2025
HER2 and urothelial carcinoma: current understanding and future directionsDaniele Raggi, Emanuele Crupi, Filippo Pederzoli, et al.
The Journal of Urology|January 10, 2016
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International CollaborationPatrizia Giannatempo, Gregory R Pond, Guru Sonpavde, et al.
Pageof 13